Biosimilar for breast cancer under Real-World scrutiny
NCT ID NCT07542496
First seen Apr 28, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This observational study is tracking 1,000 people with HER2-positive breast cancer who are receiving a pertuzumab biosimilar as part of their routine care. Researchers are looking at how the drug is used, how well it works, and any side effects in both neoadjuvant (before surgery) and first-line metastatic settings. The goal is to gather real-world data to complement findings from clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CAC BLIDA, Algiers, Algeria 16000
RECRUITINGAlgiers, Algeria
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Béni Messous, Algiers, Algeria 16000
RECRUITINGAlgiers, Algeria
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pertuzumab biosimilar
What this could lead to
If successful, this study could provide real-world evidence on how well a pertuzumab biosimilar works and is tolerated in routine care for HER2-positive breast cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection and other factors. It does not test a new drug, only gathers data on an existing biosimilar.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.